{"id":"W2899084046","doi":"10.3233/jpd-181471","title":"A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein","year":2018,"lang":"en","type":"article","venue":"Journal of Parkinson s Disease","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Institutes of Health; H. Lundbeck A/S; Eisai; Agence Nationale de la Recherche; University of Cambridge; University of British Columbia; Axial Biotherapeutics; European Commission; Acorda Therapeutics; Weston Brain Institute; Sunovion; Robert Bosch Stiftung; GlaxoSmithKline; Teva Pharmaceutical Industries; Michael J. Fox Foundation for Parkinson's Research; American Academy of Neurology; AstraZeneca","keywords":"Parkinson's disease; Clinical trial; Synucleinopathies; Alpha-synuclein; Translational research; Disease; Medicine; Drug development; Biomarker discovery; Biomarker; Clinical study design; Bioinformatics; Pathology; Biology; Pharmacology; Proteomics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08166662,0.002363113,0.00283425,0.003143492,0.00225804,0.01380914,0.004349777,0.01670134,0.02926793],"category_scores_gemma":[0.05951572,0.001145315,0.00516943,0.001679864,0.003488823,0.01100888,0.006386018,0.0174753,0.01329557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004680219,"about_ca_system_score_gemma":0.04992146,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001145671,"about_ca_topic_score_gemma":0.00202446,"domain_scores_codex":[0.9707416,0.01758264,0.002875156,0.001951761,0.004571595,0.002277336],"domain_scores_gemma":[0.9309232,0.0308558,0.005836801,0.002705257,0.01995554,0.009723442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.006039898,0.002753907,0.001625543,0.01549828,0.0008429748,0.001285312,0.0007852124,0.01011066,0.01316746,0.1869429,0.2251964,0.5357516],"study_design_scores_gemma":[0.00690324,0.01803059,0.002652429,0.01132601,0.001254074,0.0008396461,0.0009140769,0.008050562,0.006383872,0.2529202,0.6904019,0.0003234908],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.007706302,0.1046047,0.1583727,0.6301144,0.02772251,0.01363117,0.004486374,0.002706596,0.0506552],"genre_scores_gemma":[0.09007304,0.1346815,0.4789456,0.2212942,0.01515244,0.02707915,0.008052151,0.0009473643,0.02377462],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.08166662,"threshold_uncertainty_score":0.4318995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209460531511432,"score_gpt":0.4036362395024081,"score_spread":0.282690186351265,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}